Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Attr, Pfizer and BridgeBio
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the New York Yankees rallying to win the World Series as they trailed the Los | The FDA has signed off on BridgeBio's Attruby (acoramidis),
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, BridgeBio has said it will provide Attruby for free for the lifetime of any patient who participated in clinical trials of the drug.
BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby
The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization.
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
FDA approves Palo Alto biotech's heart disease drug
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the opening bell Monday.
14h
Pfizer And Schlumberger Are January Bounce Candidates
Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...
FiercePharma
21h
Pfizer led industrywide sales surge in Q3 after several quarters of dominance by Eli Lilly, Novo Nordisk
After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...
STAT
5d
Doubling down on its strategy, Pfizer names its head of oncology as new research chief
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
5d
on MSN
Pfizer names oncology head Chris Boshoff as R&D chief
Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...
5d
How Pfizer is trying to make U.S. healthcare easier to navigate
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
5d
on MSN
Pfizer Names New R&D Chief
Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...
6d
on MSN
Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...
FierceBiotech
3d
Chutes & Ladders—Pfizer replaces retiring CSO with cancer chief
Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...
STAT
13d
How Pfizer used wearables to tap into the promise of an experimental drug
Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...
5d
on MSN
Pfizer names insider Chris Boshoff as R&D chief
Pfizer said on Wednesday it has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing ...
7h
Morgan Stanley Sticks to Their Hold Rating for Pfizer (PFE)
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
China
New York Stock Exchange
Food and Drug Administration
BridgeBio
Attruby
Feedback